UNSPSC 51171960: Ramixotidine

This classification denotes a histamine-2 receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 957W618927. European Medicines Agency schedules Ramixotidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10250MIG. Ramixotidine generally arises in the molecular formula C16H21N3O3S.

UNSPSC 51171960 Ramixotidine is a Commodity code covering a specific pharmaceutical product, but recent state and local opportunities show minimal direct procurement of ramixotidine itself; instead, the opportunities reflect broader pharmaceutical and drug-testing services procurement patterns in which ramixotidine may be one component. State and local governments buying under related pharmaceutical codes pursue generic pharmaceuticals, over-the-counter products, and drug-testing services through established wholesale channels and direct-to-manufacturer models. The issuing bodies include state health and human services commissions, county supervision and corrections departments, and multistate cooperative purchasing alliances serving state agencies and local health facilities. Work solicited ranges from drug specimen collection and immunoassay screening with confirmation testing to bulk generic pharmaceutical supply through wholesaler networks and exploratory direct-to-manufacturer pharmacy programs.

The most recent activity spans Texas and Minnesota. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—an information-gathering phase without formal evaluation or award value. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for Offender Specimen Collection and Drug Testing Services due July 23, 2026, with an estimated contract value of $600,000 over two years, encompassing screening and confirmation testing across two sites with approximately 25,031 annual tests. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products due March 26, 2026, requiring vendor certification under current Good Manufacturing Practices and the Drug Supply Chain Security Act, with products supplied through three authorized wholesalers and contract terms effective July 1, 2026. The code shows limited direct ramixotidine procurement; opportunities cluster around pharmaceutical supply aggregation and specimen-testing services rather than single-drug procurements.